In this regard, it will be interesting to observe the results of the ongoing trial with the IFN-γ blocking antibody Emapalumab (trial NCT04324021) and how this affects the inflammatory situation in COVID-19 patients and the overall clinical outcome. Here, IFNG is linked to COVID-19.